[Medullary thyroid carcinoma and multiple endocrine neoplasia type 2]. / Das medulläre Schilddrüsenkarzinom und die multiple endokrine Neoplasie Typ 2.
Dtsch Med Wochenschr
; 145(17): 1245-1251, 2020 08.
Article
em De
| MEDLINE
| ID: mdl-32634843
ABSTRACT
Medullary thyroid carcinoma (MTC) is a rare malignancy and compromises only 3â% of all thyroid carcinomas. MTC cells secret calcitonin, which serves as a sensitive tumor marker for screening and follow-up of MTC. Calcitonin screening in patients with nodular goiter allows for early diagnosis of MTC and surgical curative treatment. In 25â% of patients MTC occurs as an integral part of multiple endocrine neoplasia type 2 (MEN2), an autosomal dominant inherited tumor syndrome. It is caused by germline mutations in the RET protooncogene. In gene carriers early diagnosis and treatment through prophylactic thyroidectomy is possible. MTC is a slowly growing tumor with a good prognosis and 5 and 10 year survival rates up to 80 and 60â%. In the follow-up a dynamic risk stratification allows for a personalized disease management. In symptomatic and progressive metastasizing MTC tyrosine kinase inhibitors are an effective therapy.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Glândula Tireoide
/
Carcinoma Neuroendócrino
/
Neoplasia Endócrina Múltipla Tipo 2a
Tipo de estudo:
Screening_studies
Limite:
Humans
Idioma:
De
Ano de publicação:
2020
Tipo de documento:
Article